Enhancement of the anti-tumor immune response using a combination of interferon-γ and B7 expression in an experimental mammary carcinoma

International Journal of Cancer

Volumn 77, Issue 1, 1998, Pages 107-113

  Hurwitz, Arthur A ^a   Tonsend, Sarah E ^a,b   Yu, Tina F Y ^a   Wallin, Jeanette A ^a   Allison, James P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; GAMMA INTERFERON;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; FLOW CYTOMETRY; GENE TRANSFER; GRAFT REJECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD80; CARCINOMA; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; INTERFERON TYPE II; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C;

EID: 0032479141     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980703)77:1<107::AID-IJC17>3.0.CO;2-B     Document Type: Article

References (28)

1. ALLISON, J.P., CD28-B7 interactions in T cell activation. Curr. Opin. Immunol., 6, 414-419 (1994).
2. ALLISON, J.P., HURWITZ, A.A. and LEACH, D.R., Manipulation of costimulatory signals to enhance antitumor T cell responses. Curr. Opin. Immunol., 7, 682-686 (1995).
3. BASKAR, S., GLIMCHER, L., NABAVI, N., JONES, R.T. and OSTRANDROSENBERG, S., Major histoeompatibility complex class II+B7-1 + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. exp. Med., 181, 619-629 (1995).
4. CAUX, C., VANBERVLIET, B., MASSACRIER, C., AZUMA, M., OKUMURA, K., LAMER, L. and BANCHEREAU, J., B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J. exp: Med., 180, 1841-1847 (1994).
5. CHEN, L., ASHE, S., BRADY, W.A., HELLSTRÖM, I., HELLSTRÖM, K.E., LEDBETTER, J.A., MCGOWAN, P. and LINSLEY, P.S., Co-stimulation of anti-tumor immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 71, 1093-1102 (1992).
6. CHEN, L., MCGOWAN, P., ASHE, S., JOHNSTON, J., LI, Y., HELLSTRÖM. I. and HELLSTRÖM, K.E., Tumor immunogenicity determines the effect of B7 co-stimulation on T cells-mediated tumor immunity. J. exp. Med., 179, 523-532 (1994).
7. COUGHLIN, CM., WYSOCKA, M., KURZAWA, H.L., LEE, W.M., TRINCHIHRI, G. and ECK, S.L., B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res., 55, 4980-4987 (1995).
8. DENFELD, R.W., DIETRICH, A., WUTTIG, C., TANCZOS, E., WEISS, J.M., VANSCHEIDT, W., SCHOPF, E. and SIMON, J.C., In situ expression of B7 and CD28 receptor families in human malignant melanoma: relevance for T-cell-mediated anti-tumor immunity. Int. J. Cancer, 62, 259-265 (1995).
9. DIJKMANS, R. and BILLAU, A., Interferon gamma: a master key in the immune system. Curr. Opin. Immunol., 1, 269-274 (1988).
10. DRANOFF, G., JAFFEE, E., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARDOLL, D. and MULLIGAN. R.C., Vaccina tion with irradiated tumor cells engineered to secrete murine granulocytemacrophage colony-stimulating factor stimulates potent, specific, longlasting anti-tumor immunity. Proc. net. Acad. Sci. (Wash.), 90, 3539-3543 (1993).
11. FEARON, E., PARDOLL, D., ITAYA, T., GOLUMBEK, P., LEVTTSKY, H., SIMONS, J., KARASUYAMA, H., VOGELSTEIN, B. and FROST, P., Interleukin-2 production by tumor cells bypasses T helper function in the generation of an amitumor response. Cell, 60, 397-403 (1990).
12. FREEMAN, G.J., GRIBBEN, J.G., BOUDDIONTIS, V.A., NG, J.W., RESTIVO, V.A.J., LOMBARD, L.A and NADLER, L.M., Cloning of B7-2: a CTLA-4 counter-receptor that co-stimulates human T cell proliferation. Science, 262, 909-911 (1993).
13. GANSBACHER, B., BANNERJI, R., DANIELS, B., ZIER, K., CRONIN, K. and GILBOA, E., Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Concertos., 50, 7820-7825 (1990).
14. GOLUMBEK, P., LAZANRY, H., LEVTTSKY, H., JAFFEE, L., KARASUYAMA, H., BAKER, M. and PARDOLL, D.M., Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science, 254, 713-716 (1991).
15. GUZMAN, R.C., OSBORN, R.C., SWANSON, S.M., SAKTHIVEL, R., HWANG, S.I., MIYAMOTO, S. and NANDI, S., Incidence of c-Ki-ras activation in N-methyl-N-nitrosourea-induced mammary carcinomas in pituitaryisografted mice. Cancer Res., 52, 5732-5737 (1992).
16. HUANG, A.Y., BRUCE, A.T., PARDOLL, D.M. and LEVITSKY, H.I., Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. exp. Med., 183, 769-776 (1996).
17. INABA, K., INABA, M., ROOMANI, N., AYA, H., DEGUCHI, M., IKEHARA, S., MURAMATSU, S. and STEINMAN, R.M., Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. exp. Med., 176, 1693-1702 (1992).
18. KATSANIS, E., BAUSERO, M.A., PANOSKALTSIS-MORTARI, A., DANCISAK, B.B., XU, Z., ORCHARD, P.J., DAVIS, C.G. and BLAZAR, B.R., Irradiation of singly and doubly transduced murine neuroblustoma cells expressing B7-1 and producing interferan-gamma reduces their capacity to induce systemic immunity. Cancer Gene Ther., 3, 75-82 (1996).
19. LEVITSKY, H., LAZENBY, A., HAYASHI, R.J. and PARDOLL, D.M., In vivo priming of two distinct anti-tumor effector populations: the role of MHC class I expression. J. exp. Med., 179, 1215-1224 (1994).
20. LINSLEY, P.S., GREENE, J.L., BRADY, W., BAJORATH, J., LEDBETTER, J.A. and PEACH, R., Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidity's but distinct kinetics to CD28 and CTLA-4 receptors. Immunity, 1, 793-801 (1994).
21. LUSTER, A.D. and LEDER, P., IP-10, a C-X-C chemokine, Elicits a potent thymus-dependent antitumor response in vivo, J. exp. Med., 178, 1057-1065 (1993).
22. MORRISSEY, P.J., BRESSLER, L., PARK, L.S., ALPERT, A. and GILLIS, S., Granulocyte-macrophage colony stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J. Immunol., 139, 1113-1119 (1987).
23. MULE, J.J., CUSTER, M.C., TRAVIS, W.D. and ROSENBERG, S.A., Cellular mechanisms of the anti-tumor activity of recombinant IL-6 in mice. J. Immunol., 148, 2622-2629 (1992).
24. REITER, Z., Interferon - a major regulator of natural killer cell-mediated cytotoxicity. J. Interferon Res., 13, 247-257 (1993).
25. + T cells by B7-transfected melanoma cells. Science, 259, 368-370 (1993).
26. WATANABE, Y., KURIBAYASHI, K. and MIYATAKE, S., Exogenous expression of mouse interferon γ cDNA in mouse neuroblastoma cells C1300 cells results in reduced tumorigenicity by augmented antitumor immunity. Proc. not. Acad. Sci. (Wash.), 86, 9456-9462 (1989).
27. WU, T.C., HUANC, A.Y., JAFFEE, E.M., LEVITSKY, H.I. and PARDOLL, D.M., A reassessment of the role of B7-1 expression in tumor rejection. J. exp. Med., 182, 1415-1421 (1995).
28. ZITVOGEL, L., ROBBINS, P.D., STORKUS, W.J., CLARKE, M.R., MAEURER, M.J., CAMPBELL, R.L., DAVIS, G.G., TAHARA, H., SCHREIBER, R.D. and LOTZE, M.T., Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Europ. J. Immunol., 26, 1335-1341 (1996).